March 18, 2008 — Cardinal Health and GE Healthcare announced an agreement today to broaden the availability of GE Healthcare’s Myoview™ (Tetrofosmin) cardiac imaging agent through Cardinal Health’s leading network of specialized nuclear pharmacies.
The agreement will give Cardinal Health’s customers greater access to Myoview™, a leading myocardial perfusion imaging technetium agent used in the diagnosis and treatment of heart disease.
“With this agreement, Myoview will over time become the flagship branded cardiac imaging agent offered through Cardinal Health’s nuclear pharmacies,” said John Rademacher, president, Nuclear and Specialty Pharmacy Services for Cardinal Health. “Our commitment to the nuclear pharmacy business runs deep, and partnering with GE Healthcare to provide broader access to their product portfolio illustrates the unique way Cardinal Health can bring service and value to our customers and the nuclear medicine community.”
Cardinal Health operates the largest radiopharmacy network in the United States with more than 150 nuclear pharmacy locations. It is also the largest employer of nuclear pharmacists in the world. The combination of that expertise and the size of its network allows Cardinal Health to reach 85 percent of all U.S. hospitals within three hours and provide service and clinical expertise to the nuclear medicine community.
“GE Healthcare and Cardinal Health are ideal collaborators to advance the field of nuclear medicine,” said John Chiminski, president and CEO of Medical Diagnostics at GE Healthcare. “Myoview has been a strong and growing brand in the nuclear cardiac imaging market for more than a decade, and partnering to bring it to Cardinal Health’s radiopharmacies will help clinicians reach even more patients.”
“We are committed to continually investing in nuclear medicine,” said Chiminski. “We believe working together with Cardinal Health will help us to do just that.”
ABOUT CARDINAL HEALTH
Headquartered in Dublin, Ohio, Cardinal Health, Inc. (NYSE: CAH) is an $87 billion, global company serving the health care industry with products and services that help hospitals, physician offices and pharmacies reduce costs, improve safety, productivity and profitability, and deliver better care to patients. With a focus on making supply chains more efficient, reducing health care-associated infections and breaking the cycle of harmful medication errors, Cardinal Health develops market-leading technologies, including Alaris® IV pumps, Pyxis® automated dispensing systems, MedMined™ electronic infection surveillance service, VIASYS® respiratory care products and the CareFusion™ patient identification system. The company also manufactures medical and surgical products and is one of the largest distributors of pharmaceuticals and medical supplies worldwide. Ranked No. 19 on the Fortune 500, Cardinal Health employs more than 40,000 people on five continents. More information about the company may be found at www.cardinalhealth.com
ABOUT GE HEALTHCARE
GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, performance improvement, drug discovery, and biopharmaceutical manufacturing technologies is helping clinicians around the world re-imagine new ways to predict, diagnose, inform, treat and monitor disease, so patients can live their lives to the fullest.
GE Healthcare's broad range of products and services enable healthcare providers to better diagnose and treat cancer, heart disease, neurological diseases and other conditions earlier. Our vision for the future is to enable a new 'early health' model of care focused on earlier diagnosis, pre-symptomatic disease detection and disease prevention. Headquartered in the United Kingdom, GE Healthcare is a $17 billion unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employs more than 46,000 people committed to serving healthcare professionals and their patients in more than 100 countries. For more information about GE Healthcare, visit our website at www.gehealthcare.com.
ABOUT MYOVIEW, SELECT SAFETY INFORMATION
Myoview™ (technetium Tc-99m Tetrofosmin) In studying patients with known or suspected coronary artery disease, care should be taken to ensure continuous cardiac monitoring and the availability of emergency cardiac treatment. As with all injectable drug products, allergic reactions and anaphylaxis may occur. Pharmacologic induction of cardiovascular stress may be associated with serious adverse events such as myocardial infarction, arrhythmia, hypotension, bronchoconstriction, and cerebrovascular events. Caution should be used when pharmacologic stress is selected as an alternative to exercise; it should be used when indicated and in accordance with the pharmacologic stress agent’s labeling. The most common adverse reactions reported from post-marketing experience with Myoview included rash, urticaria, abnormal vision, allergic reactions, and fever.
Before use of the product please refer to the product’s full prescribing information, available at www.myoview.com